2015 American Transplant Congress
Survival Benefit of ECD Transplantation After Ultra-Long Dialysis Exposure: Implications for Acceptance in the New KAS
Division of Nephrology, University of British Columbia, Vancouver, BC, Canada.
The survival benefit of ECD transplantation varies with the duration of pre-transplant dialysis exposure.We analyzed the survival benefit of ECD transplantation (Kidney Donor Profile Index…2015 American Transplant Congress
Defining the Epidemiologic Landscape of HIV-Infected Deceased Donors in the United States
Surgery, Johns Hopkins University, Baltimore, MD.
The HIV Organ Policy Equity Act mandates research on the use of HIV-infected (HIV+) deceased donors (HIVDD) for transplantation in HIV+ recipients. The only data…2015 American Transplant Congress
Should Only Active Candidates Define the EPTS Top 20% in the New Kidney Allocation System (KAS)?
1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Yale, New Haven, CT.
Background: The 20% of kidney candidates with the highest Estimated Post-Transplant Survival (EPTS) receive priority for a high longevity kidney in the Organ Procurement and…2015 American Transplant Congress
Microvascular Inflammation in Early Protocol Biopsies of Renal Allografts in Cases of Chronic Active Antibody-Mediated Rejection
Aim:Chronic active antibody-mediated rejection (chronic ABMR) is one important cause of late-stage renal allograft loss. However, few reports have used protocol biopsy to observe changes…2015 American Transplant Congress
DSA MFI Does Not Predict Late Antibody-Mediated Rejection Lesions Or Gene Expression Changes in Kidney Transplants
BACKGROUND: It is unclear whether donor-specific HLA antibody (DSA) levels at the time of a clinically-indicated biopsy can be predictive of the degree of antibody-mediated…2015 American Transplant Congress
De Novo DSA Would Not Necessarily Cause Graft Rejection After Renal Transplantation: Characteristics of DSA Developing Biopsy-Proven Chronic Antibody-Mediated Rejection
Kidney Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Introduction:De novo donor-specific HLA antibodies (dn DSA) production after renal transplantation has been reported to be associated with chronic antibody mediated rejection (CAMR), which leads…2015 American Transplant Congress
Part II: Rates and Determinants of Progression for De Novo Donor-Specific Antibody Mediated Kidney Allograft Injury
The development of de novo donor-specific antibody (dnDSA) is an independent predictor of allograft loss in renal transplantation. Rates and determinants of clinical pathologic progression…2015 American Transplant Congress
Impact of Donor Specific Antibodies in the Older Kidney Transplant Recipient
Houston Methodist Hospital, Houston.
Recent evidence suggests that renal transplant recipients (RTR) with both rejection and donor specific antibodies (DSA) are at high risk of graft loss. Concurrently, the…2015 American Transplant Congress
Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment
Intro: Limited options are available for treatment of ABMR in highly-HLA sensitized patients (HS). Treatment options include I+R, PLEX+I+/- R, C5-inhibitor & bortezomib. Approximately 25%…2015 American Transplant Congress
Late Antibody-Mediated Rejection in a Large Cross-Sectional Cohort of Kidney Transplant Recipients – Results of the Screening Phase of the BORTEJECT Study
Antibody-mediated rejection (ABMR) is well established to be a leading cause of graft failure. Here, we investigated the prevalence of late ABMR in a large…
American Transplant Congress abstracts